Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.
-
Upload
amelia-turner -
Category
Documents
-
view
213 -
download
0
Transcript of Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.
![Page 1: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/1.jpg)
Melanoma
INTERACTIVE CANCER CASES DISCUSSIONRome, April 3-4, 2009
![Page 2: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/2.jpg)
Antonio DR: 65 aa.
Anamnesi:
- ipertensione (in trattamento)
- Non- fumatore
- Lieve ipercolesterolemia (220 md/dl)
![Page 3: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/3.jpg)
1999
Asportazione di “nevo displastico” della spalla sx
Es. ISTOLOGICO: “melanoma maligno a cellule epitelioidi, ulcerato. Margini liberi per 2 cm. Spessore sec. Breslow = 2,1 mm. Livello sec. Clark= IV”
TAC torace-addome: negativa
![Page 4: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/4.jpg)
Stadio sec AJCC 1992
pT3N0M0 (stadio IIa) *
* American Joint Commitee on Cancer Staging (AJCC) 1992
![Page 5: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/5.jpg)
Buzaid et al, J Clin Oncol 15: 1039-1051, 1997
![Page 6: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/6.jpg)
McCain had Stage IIA melanoma in 2000
“Melanoma History Suggests McCain Has 22% Odds of Not Surviving a First Term”
Lancet 372: 1462, 2008 (Correspondence by J. Alam)
![Page 7: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/7.jpg)
Quale sarebbe stato il tasso di sopravvivenza a 5 anni stimato secondo AJCC 2002?
A) Invariato
B) 80%
C) 20%
D) circa 50%
?
![Page 8: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/8.jpg)
• Thickness thresholds of 1.0, 2.0 and 4.0 mm
• Level of invasion is used only for defining T1 melanomas
• Ulceration included as a second determinant of T and N staging
Pincipali differenze AJCC 2002 vs 1992
![Page 9: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/9.jpg)
Optimal cut-off for thickness
Buzaid et al, J Clin Oncol 15: 1039-1051, 1997
![Page 10: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/10.jpg)
Limits of Clark’s level of invasion
Buzaid et al, J Clin Oncol 15: 1039-1051, 1997
![Page 11: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/11.jpg)
Prognostic value of ulceration
![Page 12: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/12.jpg)
Stadio sec. AJCC 2002
AJCC Cancer staging manual, 6th edition, 2002
![Page 13: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/13.jpg)
Survival rates according to the AJCC 2002 staging system
Balch et al, JCO 19: 3635-3648, 2001
![Page 14: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/14.jpg)
!5 yrs survival curves for the stage groupings for patients with localized melanoma
Balch et al, JCO 19: 3635-3648, 2001
![Page 15: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/15.jpg)
Da valutare:
• Appropriatezza dei margini chirurgici
• Staging linfonodale (SLNB)
• Imaging
• Terapia adiuvante
![Page 16: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/16.jpg)
Can J Surg 46: 419-426, 2003
![Page 17: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/17.jpg)
NEJM 350: 757-766, 2004
![Page 18: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/18.jpg)
Principles of surgical margins for wide excision of primary melanoma
Tumor thickness Recommendend clinical margins
in situ 0.5 cm
≤ 1 mm 1.0 cm
1.01-2 mm 1-2 cm
2.01-4 mm 2.0 cm
> 4 mm 2.0 cm
American Society of Plastic Surgeons
![Page 19: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/19.jpg)
3rd interim analysis of the MSLT-I trial
1400 pts.
Breslow 1.2-3.5 mm
![Page 20: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/20.jpg)
Morton et al, NEJM 355: 1307-1318, 2006
![Page 21: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/21.jpg)
Incidence of positive SLN according to thickness
≥ 4 mm 30-50%
Wong, Ann Surg Oncol 13: 302-309, 2006
Gershenwald, Ann Surg Oncol 7: 160-165, 2000Gutzmer, J Dtsch Dermatol Ges 6: 198-203, 2008
![Page 22: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/22.jpg)
Stage indication
In situ (0) not indicated
IA (≤ 1 mm) consider in case of adverse prognostic features (high mitotic index, linfovascular invasion, > 0.75 mm)
IB (≤ 1 mm, Clark ≥ IV ulcerated or >1 mm) use encouraged
Recommendations on the use of SLNB
![Page 23: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/23.jpg)
?
Ritenete che le indagini radiologiche eseguite fossero sufficienti a definire lo stadio?
A) No
B) Si
![Page 24: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/24.jpg)
• Stage I (≤ 2mm, no ulceration)
Routine imaging not recommended
• Stage II (> 4 mm ± ulceration)
As clinically indicated
• Stage III (N+)
Extend of imaging left at the discretion of the physician
Pelvic CT for inguinophemoral lymphoadenopathy
• Stage IV (M+)
LDH + chest X-ray recommended
Abdominal/pelvic CT ± PET should be considered
Brain CT or MRI in symptomatic patients
![Page 25: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/25.jpg)
• Stage I and IIA• should not be staged by imaging
• Stage IIB* and overChest x-ray and liver US
orCT scan chest, adbomen ± pelvisLiver function tests, LDH, full blood count
* It may be reasonable to omit
![Page 26: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/26.jpg)
Yankovitz, Cancer 110: 1107-1113, 2007
![Page 27: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/27.jpg)
?
Ritenete che in questo caso un trattamento adiuvante con IFN-a avrebbe garantito un vantaggio in termini di PFS e OS?
A) No
B) Si
![Page 28: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/28.jpg)
Main trials on low-intermediate dose IFN in stage IIb-III patients
• Cascinelli (WHO trial, Lancet 2001): N. 444, 3MU 3dd/w for 3 yrs
No improvement in DFS or OS
• Grobb (French trial, Lancet 1998): N. 449, 3MU 3dd/w for 18 mos
Improved PFS, trend for OS (not confirmd at 41 mos)
• Hancock (AIM-HIGH trial, JCO 2004): N. 674, 3MU 3dd/w for 2 yrs
No improvement in DFS or OS
• Eggermont (EORTC 18952, Lancet 2005): N 1388, 10 MU 5dd/w for 4 wks followed by 10MU 3 dd/w for 1 y
No improvement in DFS or OS
![Page 29: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/29.jpg)
Adjuvant HD IFN in stage IIb-III melanoma
• Kirkwood (ECOG 1684, JCO 1996): HDI vs observationBenefit in DFS and OS at 7 yrsBenefit in OS disappeared at 13 yrs
• Kirkwood (ECOG 1690, JCO 2000): HDI vs observationBenefit in DFS not in OS
• Kirkwood (ECOG 1694, JCO 2001): HDI vs GMK vaccineHDI better for DFS and OS(only 2y FU and no observation arm)
![Page 30: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/30.jpg)
Toxicities of Adjuvant HD IFN
• Overall G3-4 toxicity: 78%
• Fatigue,Flu-like symptoms, myalgias, fever 20-25%
• Depression 40-70%
• Suicidal ideation 5-10%
• Autoimmune disorders 10%
(hypo-hyperthiroidism, vitiligo, LES, rheumatoid arthritis ecc)
Associated with improved PFS and OS.
![Page 31: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/31.jpg)
“ On the basis of the published data, adjuvant HDI therapy does not seem to reduce risk of death from melanoma in those patients at highest risk of this outcome” (Nature Clin Pract Oncol 5: 4-5, 2008)
“ Among all the trials of adjuvant therapy for intermediate or high risk melanoma reported to date, no therapy has ever achieved the durable RFS and independently significant OS benefits that have been observed with HDI” (Nature Clin Pract Oncol 5: 2-3, 2008)
![Page 32: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/32.jpg)
JCO 20: 18181-1825, 2002
![Page 33: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/33.jpg)
JCO 20: 18181-1825, 2002
“Although ECOG 1684 and ECOG 1690 (HDI vs observation) reported statistically significant benefit for DFS…our analysis confirmed this only for EOTC 1684.
For OS, ECOG 1684 trial reported benefit for IFN-a, but our analysis did not confirm it.
![Page 34: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/34.jpg)
• Stage 0, IA
no adjuvant therapy recommended
• Stage IB, IIA
clinical trial or observation
• Stage IIB-C, III
IFN, clinical trial or observation
• Patients rendered free of disease after surgery
(stage III in-transit metastasis or stage IV)
consideration of adjuvant treatment is appropriate
![Page 35: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/35.jpg)
“Decision on the appropriateness of adjuvant IFN should be made on an individual basis, after discussion with the patient, including an explanation of the potential benefits and side effects”
![Page 36: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/36.jpg)
Marzo 2005
TAC TORACE:
“multiple lesioni polmonari bilaterali, noduli sottocutanei in regione mammaria sx e nodulo in regione ascellare sx”
BIOPSIA NODULO SOTTOCUTANEO:
Metastasi da melanoma
![Page 37: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/37.jpg)
?
Quale dei seguenti parametri ematochimici ritenete abbiano valore prognostico nel melanoma metastatico?
1) Albumina
2) Emoglobina
3) Transaminasi
4) LDH
![Page 38: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/38.jpg)
JCO 16:1103-1111, 1998
Retrospective, 400 pts
![Page 39: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/39.jpg)
AJCC 2002
![Page 40: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/40.jpg)
Trattamento melanoma metastatico
• Chemioterapia ORR 5-20%
• Immunoterapia (HD IL-2) ORR 10-25% (CR 6%)
• Biochemioterapia ORR 10-30%
![Page 41: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/41.jpg)
?
Ritenete che una polichemioterapia offra un vantaggio di sopravvivenza rispetto ad una mono-chemioterapia?
A) NO
B) SI
![Page 42: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/42.jpg)
Different polychemiotherapy regimens have not shown prolongation of survival in comparison with dacarbazine.
Objective response rates 5-28% were obtained with single agent dacarbazine, while the polychemiotherapy schedules achieved slightly higher response rates (12-37%)
Lancet Oncol, 4: 748-759, 2003
![Page 43: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/43.jpg)
“The increased response observed with biochemiotherapy (chemo ± IFN ± IL-2) associated with increased toxicity and no significant improvement in survival”.
![Page 44: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/44.jpg)
However…
“.. In certain clinical situations, an increased response rate may be an important therapeutic outcome, perhaps leading to better symptom control or rendering a tumor mass operable.This needs to be balanced against the increased toxicity associated with the approach”
![Page 45: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/45.jpg)
Marzo 2005:quale trattamento?
• Dacarbazina 250 mg/m2/d for5 q21dd
Somministrati 6 cicli con SD
Principale tossicità: piastrinopenia G3
![Page 46: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/46.jpg)
Settembre 2005
• TAC torace-addome-encefalo:
“ Comparsa di multiple localizzazioni cerebrali a carico di entrambi gli emisferi”
![Page 47: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/47.jpg)
JCO 18: 158-166, 2000
305 PATIENTS R
Dacarbazine(250 mg/m2/d for 5 days, q21d
Temozolomide(200 mg/m2/d for 5 dd q28d)
![Page 48: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/48.jpg)
JCO 18: 158-166, 2000
Median PFS: 1.9 vs 1.5 mos (p= 0.012)
Median OS: 7.9 vs 5.7 mos (p= 0.06)
![Page 49: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/49.jpg)
Settembre 2005
• WBRT 30 gray in 10 frazioni (gg 1-5, 8-12) + Temozolomide 75 mg/m2/d dal g1 per 6 settimane (come glioblastoma)
• Dopo 4 settimane: temozolomide 200 mg/m2/die per 5 gg q28 per 3 cicli
![Page 50: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/50.jpg)
Dicembre 2005
• TAC torace-addome-encefalo:
“Comparsa di lesioni epatiche multiple. Aumentate di volume lesioni polmonari”
• Il paziente viene arruolato in un trial clinico per trattamento con Talidomide
• Progressione di malattia a marzo 2006
![Page 51: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/51.jpg)
Nuove possibilità terapeutiche
Drug Target
• Sorafenib Raf, VEGFR, PDGFR• Bevacizumab VEGF• Bortezomib proteasome inhibitor• Ipilumumab CTLA-4 mAb• Vitaxin v3 integrin mAb• Oblimersen bcl-2 antisense• MS-275 histone deacetylase inhibitor
![Page 52: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/52.jpg)
ORR 13.5 vs 7.5DFS 2.6 mos vs 1. 6 mos (HR= 0.75; p= 0.02)OS 9 vs 7.8 mos (HR= 0.87, p= 0.077)
![Page 53: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/53.jpg)
![Page 54: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/54.jpg)
Stage migration (the Will Rogers phenomenon)
![Page 55: Melanoma INTERACTIVE CANCER CASES DISCUSSION Rome, April 3-4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022081518/5514302e550346dd488b5f58/html5/thumbnails/55.jpg)
“ When the Okies left Oklahoma and moved to California, they raised the average intelligence level in both states”
R: {1, 2 } media= 1.5
S: {99,10000,20000} media= 10033
STAGE MIGRATION
R: {1, 2, 99 } media= 34
S: {10000,20000} media= 15000